Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Leukemia Cells ◽

Cyclin Dependent Kinase ◽

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells

Leukemia ◽

10.1038/sj.leu.2403295 ◽

2004 ◽

Vol 18 (4) ◽

pp. 747-755 ◽

Cited By ~ 90

Author(s):

I N Hahntow ◽

F Schneller ◽

M Oelsner ◽

K Weick ◽

I Ringshausen ◽

...

Keyword(s):

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Leukemia Cells ◽

Cyclin Dependent Kinase ◽

Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway

Leukemia & Lymphoma ◽

10.1080/10428194.2016.1187276 ◽

2016 ◽

Vol 58 (1) ◽

pp. 199-203 ◽

Cited By ~ 2

Author(s):

Leona Raskova Kafkova ◽

Veronika Navrkalova ◽

Marie Jarosova ◽

Tomas Loja ◽

Jana Chovancova ◽

...

Keyword(s):

Dna Damage ◽

Signaling Pathway ◽

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Leukemia Cells ◽

Cyclin Dependent Kinase ◽

P53 Signaling ◽

P53 Signaling Pathway

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Leukemia ◽

10.1038/leu.2012.144 ◽

2012 ◽

Vol 26 (12) ◽

pp. 2554-2557 ◽

Cited By ~ 54

Author(s):

A J Johnson ◽

Y-Y Yeh ◽

L L Smith ◽

A J Wagner ◽

J Hessler ◽

...

Keyword(s):

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Leukemia Cells ◽

The Novel ◽

Cyclin Dependent Kinase ◽

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2583-9 ◽

2014 ◽

Vol 74 (5) ◽

pp. 1057-1064 ◽

Cited By ~ 31

Author(s):

Claire Fabre ◽

Marco Gobbi ◽

Cyrine Ezzili ◽

Mustapha Zoubir ◽

Marie-Paule Sablin ◽

...

Keyword(s):

Clinical Study ◽

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

The Novel ◽

Cyclin Dependent Kinase ◽

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

Leukemia ◽

10.1038/leu.2015.31 ◽

2015 ◽

Vol 29 (7) ◽

pp. 1524-1529 ◽

Cited By ~ 61

Author(s):

J Flynn ◽

J Jones ◽

A J Johnson ◽

L Andritsos ◽

K Maddocks ◽

...

Keyword(s):

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Clinical Activity ◽

Cyclin Dependent Kinase ◽

Significant Clinical Activity

High intracellular content of cyclin-dependent kinase inhibitor p27Kip1in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease

European Journal Of Haematology ◽

10.1111/j.1600-0609.2008.01196.x ◽

2009 ◽

Vol 82 (4) ◽

pp. 260-266 ◽

Cited By ~ 8

Author(s):

Dariusz Wolowiec ◽

Marcin Wojtowicz ◽

Lidia Ciszak ◽

Agata Kosmaczewska ◽

Irena Frydecka ◽

...

Keyword(s):

B Cell ◽

Kinase Inhibitor ◽

Intermediate Stage ◽

Lymphocytic Leukemia ◽

Rapid Progression ◽

Cyclin Dependent Kinase ◽

Intracellular Content ◽

Cell Chronic Lymphocytic Leukemia

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells

PLoS ONE ◽

10.1371/journal.pone.0143685 ◽

2015 ◽

Vol 10 (11) ◽

pp. e0143685 ◽

Cited By ~ 17

Author(s):

Cody Paiva ◽

J. Claire Godbersen ◽

Ryan S. Soderquist ◽

Taylor Rowland ◽

Sumner Kilmarx ◽

...

Keyword(s):

B Cells ◽

P38 Mapk ◽

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Dependent Manner ◽

Cyclin Dependent Kinase ◽

Abstract 3905: Strategic combination of the cyclin-dependent kinase inhibitor CYC065 with venetoclax to target anti-apoptotic proteins in chronic lymphocytic leukemia

10.1158/1538-7445.am2018-3905 ◽

2018 ◽

Author(s):

Rong Chen ◽

Yuling Chen ◽

Sheelagh Frame ◽

David Blake ◽

William G. Wierda ◽

...

Keyword(s):

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Cyclin Dependent Kinase ◽

Apoptotic Proteins

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

Leukemia ◽

10.1038/leu.2011.109 ◽

2011 ◽

Vol 25 (9) ◽

pp. 1444-1451 ◽

Cited By ~ 32

Author(s):

K A Blum ◽

A S Ruppert ◽

J A Woyach ◽

J A Jones ◽

L Andritsos ◽

...

Keyword(s):

Risk Factors ◽

Kinase Inhibitor ◽

Tumor Lysis Syndrome ◽

Lymphocytic Leukemia ◽

Cyclin Dependent Kinase ◽

Tumor Lysis ◽

Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-16-1446 ◽

2016 ◽

Vol 23 (14) ◽

pp. 3734-3743 ◽

Cited By ~ 48

Author(s):

Viralkumar Patel ◽

Kumudha Balakrishnan ◽

Elena Bibikova ◽

Mary Ayres ◽

Michael J. Keating ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphocytic Leukemia ◽

Leukemia Cells ◽

Bruton Tyrosine Kinase